Drug Profile
Research programme: cancer therapeutics - Phio Pharmaceuticals
Alternative Names: sd-rxRNA based therapeuticsLatest Information Update: 21 Nov 2018
Price :
$50
*
At a glance
- Originator RXi Pharmaceuticals
- Developer Phio Pharmaceuticals
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action Gene silencing; Programmed cell death-1 receptor antagonists; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer